, Volume 66, Issue 4, pp 477–496 | Cite as


A Review of its Use in Essential Hypertension
  • Caroline Fenton
  • Gillian M. Keating
  • Katherine A. Lyseng-Williamson
Adis Drug Evaluation



Moxonidine (Physiotens®, Moxon®, Cynt®) is an orally administered imidazoline compound with selective agonist activity at imidazoline I1 receptors and only minor activity at α2-adrenoceptors. Moxonidine acts centrally to reduce peripheral sympathetic activity, thus decreasing peripheral vascular resistance. In patients with mild to moderate hypertension, moxonidine reduces blood pressure (BP) as effectively as most first-line antihypertensives when used as monotherapy and is also an effective adjunctive therapy in combination with other antihypertensive agents. It improves the metabolic profile in patients with hypertension and diabetes mellitus or impaired glucose tolerance, is well tolerated, has a low potential for drug interactions and may be administered once daily in most patients. Thus, moxonidine is a good option in the treatment of patients with mild to moderate hypertension, particularly as adjunctive therapy in patients with the metabolic syndrome.

Pharmacological Properties

Moxonidine is a centrally acting selective agonist at imidazoline I1 receptors, tor which it has an affinity >30-fold that for α2-adrenoceptors. Moxonidine inhibits peripheral sympathetic activity, which decreases peripheral vascular resistance and results in significant decreases in systolic and diastolic BP (SBP and DBP). Moxonidine has minimal effect on cardiac haemodynamics and reduces left ventricular mass. Markers of endothelial dysfunction and end-organ damage, including microalbuminuria, improved in hypertensive patients who achieved BP control with moxonidine. Moxonidine also improved the metabolic profile of patients with hypertension and type 2 diabetes or impaired glucose tolerance. Oral moxonidine is rapidly absorbed, although the maximum antihypertensive effect occurs 3–4 hours after administration.

Oral bioavailability is 88% and is unaffected by food. No first-pass metabolism occurs and moxonidine is mostly excreted unchanged in the urine.

Therapeutic Efficacy

In well designed, 8-week trials, monotherapy with moxonidine 0.2–0.6 mg/day reduced sitting DBP to a significantly greater extent than placebo (mean change from baseline −10.7 to −13.2 vs −2.3 to −9mm Hg) in patients with mild to moderate essential hypertension. Sitting SBP also improved from baseline to a significantly greater extent with moxonidine than with placebo (mean −19.5 to −24.9 vs −1.2 to −13mm Hg). Reductions in sitting SBP and DBP with moxonidine 0.2–0.8 mg/day at 8 weeks were similar to those with enalapril 5–20mg once daily, atenolol 50–100 mg/day (except in postmenopausal women where atenolol reduced BP to a greater extent than moxonidine), hydrochlorothiazide 25mg once daily and rilmenidine 1–2 mg/day. At 26 weeks, reductions in sitting SBP and DBP with moxonidine 0.2–0.4 mg/day were similar to those with nifedipine sustained release 20–40 mg/day.

Once-daily adjunctive moxonidine 0.4mg was also effective in patients with mild to moderate hypertension in well designed trials. In patients who did not respond to moxonidine monotherapy, mean improvements in sitting DBP at 4 weeks were −7.3mm Hg with moxonidine 0.4mg once daily plus amlodipine 5mg once daily, −4.8mm Hg with moxonidine 0.4mg once daily plus enalapril 10mg once daily and −3.2mm Hg with moxonidine 0.4mg once daily plus hydrochlorothiazide 12.5mg once daily. In another trial, changes in sitting SBP and DBP after 8 weeks’ treatment were significantly greater with once-daily moxonidine 0.4mg plus hydrochlorothiazide 25mg than with the respective monotherapies (−27 vs −20 and −22mm Hg and −16 vs −12 and −13mm Hg).


Moxonidine was generally well tolerated in clinical trials in patients with mild to moderate hypertension. In placebo-controlled monotherapy trials, 36–43% of moxonidine recipients experienced treatment-emergent adverse events versus 22–29% of placebo recipients and ≈32% and 35% of enalapril and hydrochlorothiazide recipients, respectively. Dry mouth was the most common adverse event with moxonidine monotherapy, affecting 11–20% of patients; other all-cause adverse events included diarrhoea, headache, bronchitis, nausea, dizziness and back pain. Other than dry mouth, asthenia and fatigue, adverse events in moxonidine monotherapy recipients were not generally related to α2-adrenoceptor inhibition. No new adverse events were reported in combination therapy trials.

Moxonidine was also well tolerated in a pooled analysis of postmarketing surveillance studies in 91 170 patients, about two-thirds of whom received moxonidine as monotherapy. Adverse events affected 9.4% of patients, causing 1.8% to discontinue treatment, and were generally not related to dosage, treatment duration, sex or age; dry mouth affected 4.2% of patients aged >65 years versus 2.7% of those aged <40 years.


  1. 1.
    Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289(18): 2363–9PubMedCrossRefGoogle Scholar
  2. 2.
    ESH-ESC Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21(6): 1011–53CrossRefGoogle Scholar
  3. 3.
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289(19): 2560–72PubMedCrossRefGoogle Scholar
  4. 4.
    Brookes L. New definition of hypertension proposed [online]. Available from URL: http://www.medscape.com [Accessed 2005 Jun 9]
  5. 5.
    Prichard BNC, Owens CWI, Graham BR. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. J Hum Hypertens 1997 Aug; 11 Suppl. 1: 29–45Google Scholar
  6. 6.
    Schaefer HG, Toublanc N, Weimann H-J. The pharmacokinetics of moxonidine. Rev Contemp Pharmacother 1998; 9(7): 481–90Google Scholar
  7. 7.
    Chrisp P, Faulds D. Moxonidine: a review of its pharmacology, and therapeutic use in essential hypertension. Drugs 1992 Dec; 44: 993–1012PubMedCrossRefGoogle Scholar
  8. 8.
    Ernsberger P. Pharmacology of moxonidine: an I1-imidazoline receptor agonist. J Cardiovasc Pharmacol 2000; 35 (7 Suppl. 4): S27–41PubMedCrossRefGoogle Scholar
  9. 9.
    Prichard BNC, Graham BR. The use of moxonidine in the treatment of hypertension. J Hypertens 1997 Jan; 15 Suppl. 1: 47–55Google Scholar
  10. 10.
    Schafers RF, Holzgreve H, Distler A, et al. Double blind, multicentre comparison of moxonidine and enalapril and their effects on blood pressure and left ventricular mass: results of the MOXENA study [abstract no. P1051]. J Hypertens 2002 Jun; 20 Suppl. 4: 249Google Scholar
  11. 11.
    Waters J, Ashford J, Jäger B, et al. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension: results of the TOPIC (Trial Of Physiotens In Combination) study. J Clin Basic Cardiol 1999; 2(2): 219–24Google Scholar
  12. 12.
    Kirch W, Hutt HJ, Plänitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J Clin Pharmacol 1990 Dec; 30(12): 1088–95PubMedGoogle Scholar
  13. 13.
    Mitrovic V, Patyna W, Huting J, et al. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991 Dec; 5(6): 967–72PubMedCrossRefGoogle Scholar
  14. 14.
    Greenwood JP, Scott EM, Stoker JB, et al. Chronic I1-imidazoline agonism: sympathetic mechanisms in hypertension. Hypertension 2000 Jun; 35: 1264–9PubMedCrossRefGoogle Scholar
  15. 15.
    Kirch W, Hutt HJ, Plänitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988 Oct; 15(4): 245–53PubMedCrossRefGoogle Scholar
  16. 16.
    Krespi PG, Makris TK, Hatzizacharias AN, et al. Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998 Oct; 12: 463–7PubMedCrossRefGoogle Scholar
  17. 17.
    Doumas MN, Douma SN, Petidis KM, et al. Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension. J Clin Hypertens (Greenwich) 2004 Dec; 6(12): 682–9CrossRefGoogle Scholar
  18. 18.
    Martina B, Surber C, Jakobi C, et al. Effect of moxonidine and cilazapril on microcirculation as assessed by finger nailfold capillaroscopy in mild-to-moderate hypertension. Angiology 1998 Nov; 49: 897–901PubMedCrossRefGoogle Scholar
  19. 19.
    Farsang C, Finta E, Kerkovits L, et al. Moxonidine possibly inhibits angiotensin converting enzyme inhibitor (ACEi)-induced cough in patients with essential hypertension: a multi-centre, open pilot study [abstract no. P2.216]. J Hypertens 2003 Jun; 21 Suppl. 4: 183Google Scholar
  20. 20.
    Troussov V, Acsenov C. Moxonidine (Phisiotens) in treatment of hypertension in elderly patients with type 2 diabetes mellitus [abstract no. 2543]. Diabetes Metab 2003 Aug; 29 (4 Suppl.): 314Google Scholar
  21. 21.
    Aparina T, Britov A, Gomazkov O. Effects of enalapril and moxonidine on left ventricular hypertrophy in relation to insulin resistance in hypertensive patients [abstract no. P1.198]. J Hypertens 2003 Jun; 21 Suppl. 4: 75Google Scholar
  22. 22.
    Reznik L, Koval S, Koval D, et al. The effects of moxonidine long-term monotherapy on endothelial vasoactive factors in patients with hypertension [abstract no. 99]. J Hypertens 2003 Jun; 21 Suppl. 4: 336Google Scholar
  23. 23.
    Sanjuliani AF, Genelhu de Abreu V, Ueleres Braga J, et al. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin, and metabolic profile in obese hypertensive patients. J Clin Basic Cardiol 2004; 7: 19–25Google Scholar
  24. 24.
    Orynchak MA, Neyko EM, Chovganyuk OS. Role of moxonidine in insulin secretion and endothelial dysfunction in the patients with insulin resistance [abstract no. P-538]. Am J Hypertens 2005 May 2; 18(5): 202–3Google Scholar
  25. 25.
    Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Hannover: Solvay Pharmaceuticals, 2005. (Data on file)Google Scholar
  26. 26.
    Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens Suppl 1999; 17 Suppl. 3: S29–35Google Scholar
  27. 27.
    Kaaja R, Manhem K, Tuomilehto J. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist. Int J Clin Pract 2004 Mar; Suppl. 139: 26–32Google Scholar
  28. 28.
    Jacob S, Klimm HJ, Rett K, et al. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004 Jun; 112(6): 315–22Google Scholar
  29. 29.
    Strojek K, Grzeszczak W, Górska J, et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001 Mar; 12: 602–5PubMedGoogle Scholar
  30. 30.
    Neumann J, Ligtenberg G, Oey L, et al. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004 Nov; 15(11): 2902–7PubMedCrossRefGoogle Scholar
  31. 31.
    Vonend O, Marsalek P, Russ H, et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003 Sep; 21(9): 1709–17PubMedCrossRefGoogle Scholar
  32. 32.
    He MM, Abraham TL, Lindsay TJ, et al. Metabolism and disposition of the antihypertensive agent moxonidine in humans. Drug Metab Dispos 2003 Mar; 31(3): 334–42PubMedCrossRefGoogle Scholar
  33. 33.
    Wise SD, Chan C, Schaefer HG, et al. Quinidine does not affect the renal clearance of moxonidine. Br J Clin Pharmacol 2002 Sep; 54: 251–4PubMedCrossRefGoogle Scholar
  34. 34.
    Pinthong D, Songsermsakul P, Rattanachamnong P, et al. The effects of imidazoline agents on the aggregation of human platelets. J Pharm Pharmacol 2004 Feb; 56(2): 213–20PubMedCrossRefGoogle Scholar
  35. 35.
    Wenzel RR, Mitchell A, Siffert W, et al. The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress. Br J Clin Pharmacol 2004 May; 57(5): 545–51PubMedCrossRefGoogle Scholar
  36. 36.
    El-Ayoubi R, Menaouar A, Gutkowska J, et al. Urinary responses to acute moxonidine are inhibited by natriuretic peptide receptor antagonist. Br J Pharmacol 2005 May; 45(1): 50–6CrossRefGoogle Scholar
  37. 37.
    Cao C, Kang CW, Kim SZ, et al. Augmentation of moxonidine-induced increase in ANP release by atrial hypertrophy. Am J Physiol Heart Circ Physiol 2004; 287(1): H150–6PubMedCrossRefGoogle Scholar
  38. 38.
    Moreira TS, Takakura AC, Menani JV, et al. Central blockade of nitric oxide synthesis reduces moxonidine-induced hypotension. Br J Pharmacol 2004 Jun; 142(4): 765–71PubMedCrossRefGoogle Scholar
  39. 39.
    Solvay Healthcare Limited. Physiotens tablets 200, 300 & 400 micrograms: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2005 Jun 13]
  40. 40.
    Levy BI. The importance of microcirculation and tissue perfusion in hypertension [in French]. Curr Med Res Opin 2005; 21 Suppl. 5: S1–6PubMedCrossRefGoogle Scholar
  41. 41.
    Sleight P. The sympathetic nervous system in hypertension: differing effects of drug treatment. Eur Heart J 1998 Jun; 19 Suppl. F: 39–44Google Scholar
  42. 42.
    Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation 2005 Sep; 112(17): 2735–52PubMedCrossRefGoogle Scholar
  43. 43.
    Mogensen CE. New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl 2003 Mar; 21 Suppl. 1: S25–30Google Scholar
  44. 44.
    Abellán J, Leal M, Hernández-Menárguez F, et al. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney Int Suppl 2005 Jan; 67 Suppl. 93: S20–4CrossRefGoogle Scholar
  45. 45.
    Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens 2004 Sep; 18(9): 669–75PubMedCrossRefGoogle Scholar
  46. 46.
    Frei M, Kuster L, Gardosch von Krosigk PP, et al. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24 Suppl. 1: 25–8CrossRefGoogle Scholar
  47. 47.
    Küppers HE, Jäger BA, Luszick JH, et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997 Jan; 15: 93–7PubMedCrossRefGoogle Scholar
  48. 48.
    Prichard BNC, Jäger BA, Luszick JH, et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. Blood Press 2002; 11(3): 166–72PubMedCrossRefGoogle Scholar
  49. 49.
    Prichard BNC, Küster LJ, Hughes PR, et al. Dose relation of blood pressure reduction with moxonidine: findings from three placebo- and active-controlled randomized studies. J Clin Basic Cardiol 2003; 6: 49–51Google Scholar
  50. 50.
    Camilleri G, Portal B, Quiniou G, et al. Comparison of the antihypertensive efficacy of and tolerance to two imidazoline receptor agonists: moxonidine and rilmenidine in monotherapy [in French]. Ann Cardiol Angeiol (Paris) 2001 Apr; 50(3): 169–74CrossRefGoogle Scholar
  51. 51.
    Prichard BNC, Simmons R, Rooks MJ, et al. A double-blind comparison of moxomidine and atenolol in the management of patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1992; 20 Suppl. 4: S45–9CrossRefGoogle Scholar
  52. 52.
    Wolf R. The treatment of hypertensive patients with at calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992; 20 Suppl. 4: S42–4CrossRefGoogle Scholar
  53. 53.
    Feuring M, Cassel W, Thun B, et al. Moxonidine and ramipril in patients with hypertension and obstructive pulmonary disease. Clin Drug Invest 2000 Jul; 20: 19–24CrossRefGoogle Scholar
  54. 54.
    Plänitz V. Comparison of moxonidine and clonidine HCl in treating patients with hypertension. J Clin Pharmacol 1987 Jan; 27(1): 46–51PubMedCrossRefGoogle Scholar
  55. 55.
    Plänitz V. Intraindividual comparison of moxonidine and prazosin in hypertensive patients. Eur J Clin Pharmacol 1986; 29(6): 645–50PubMedCrossRefGoogle Scholar
  56. 56.
    Trieb G, Jäger B, Hughes PR, et al. Long-term evaluation of the antihypertensive efficacy and tolerability of the orally acting imidazoline I1 receptor agonist moxonidine in patients with mild-to-moderate essential hypertension. Eur J Clin Res 1995; 7: 227–40Google Scholar
  57. 57.
    Rayner B, Coetzer E. Moxonidine is effective for controlling blood pressure in patients with resistant hypertension [abstract]. Cardiovasc J S Afr 2005 Mar; 16 (2 Suppl. 1): 20Google Scholar
  58. 58.
    Martin U, Hill C, O’Mahony D. Use of moxonidine in elderly patients with resistant hypertension. J Clin Pharm Ther 2005 Oct; 30(5): 433–7PubMedCrossRefGoogle Scholar
  59. 59.
    Cohn JN, Pfeffer MA, Rouleau J, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5(5): 659–67PubMedCrossRefGoogle Scholar
  60. 60.
    Confirmation of the effectiveness and tolerability profile of the antihypertensive moxonidine: data from 14 post-marketing surveillance studies involving >91,000 patients. Hannover: Solvay Pharmaceuticals, 2005. (Data on file)Google Scholar
  61. 61.
    Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003; 88(6): 2399–403PubMedCrossRefGoogle Scholar
  62. 62.
    Peverill RE. Hypertension guidelines, meta-analyses and clinical trials: do we assume too much? Med J Aust 2005; 182(2): 82–Google Scholar
  63. 63.
    Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22: 1543–8CrossRefGoogle Scholar
  64. 64.
    Rayner B. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? Curr Med Res Opin 2004 Mar; 20(3): 359–67PubMedCrossRefGoogle Scholar
  65. 65.
    Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens 2004; 22: 1845–7PubMedCrossRefGoogle Scholar
  66. 66.
    Kaaja RJ, Pöyhönen-Alho MK. Insulin resistance and sympathetic overactivity in women. J Hypertens 2005; 24: 131–41CrossRefGoogle Scholar
  67. 67.
    Pater C, Bhatnagar D, Berrou J-P, et al. A novel approach to treatment of hypertension in diabetic patients: a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of eprosartan versus ramipril with low-dose hydrochlorothiazide and moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2. Rationale and design [ISRCTN55725285]. Curr Control Trials Cardiovasc Med 2004 Oct 1; 5(1): 9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Caroline Fenton
    • 1
  • Gillian M. Keating
    • 1
  • Katherine A. Lyseng-Williamson
    • 1
  1. 1.Adis International LimitedAucklandNew Zealand

Personalised recommendations